Medicus Pharma's SkinJect Phase 2 Data Validated by KOL, Shows 80% Response Rate
Event summary
- Medicus Pharma's Phase 2 SkinJect data validated by KOL Dr. Babar Rao, showing 80% overall response rate in nodular basal cell carcinoma (BCC) patients.
- Study design isolates therapeutic contribution of doxorubicin, demonstrating clinical and histological clearance endpoints.
- 200µg dose cohort achieved 73% clinical clearance and 40% histological clearance, selected as lead regimen for further development.
- Dr. Rao highlights potential for SkinJect as non-surgical treatment alternative, particularly for patients with limited access to Mohs surgery.
- Medicus Pharma exploring collaborations with Helix Nanotechnologies for mRNA vaccine development and Reliant AI for AI-driven clinical data analytics.
The big picture
Medicus Pharma's validation of SkinJect Phase 2 data by a key opinion leader reinforces the clinical meaningfulness of the dataset and supports continued development and regulatory engagement. The study's rigorous design and promising results position SkinJect as a potential non-surgical treatment alternative for nodular BCC patients, addressing a significant unmet need in dermatology. The company's strategic collaborations aim to accelerate clinical development and expand the SkinJect platform, potentially unlocking substantial market opportunities.
What we're watching
- Regulatory Pathway
- Whether Medicus Pharma can secure an EOP2 meeting with the FDA in the first half of 2026 to discuss the conversion of the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial.
- Commercial Potential
- The pace at which Medicus Pharma can advance the SKNJCT-004 study and expand the SkinJect platform into the United Kingdom, tapping into the ~$2 billion market opportunity for non-melanoma skin diseases.
- Strategic Collaborations
- How the non-binding collaborations with Helix Nanotechnologies and Reliant AI will progress, and whether definitive agreements will be executed to support the development of thermostable infectious disease vaccines and AI-driven clinical data analytics.